ADAPTIVE BIOTECHNOLOGIES COR's ticker is ADPT and the CUSIP is 00650F109. A total of 230 filers reported holding ADAPTIVE BIOTECHNOLOGIES COR in Q2 2021. The put-call ratio across all filers is 0.39 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $174,215 | -67.5% | 31,966 | -60.0% | 0.00% | – |
| Q2 2023 | $536,062 | +59.8% | 79,890 | +110.3% | 0.00% | – |
| Q1 2023 | $335,443 | -36.2% | 37,989 | -44.8% | 0.00% | – |
| Q4 2022 | $526,059 | +314.2% | 68,856 | +286.6% | 0.00% | – |
| Q3 2022 | $127,000 | -96.2% | 17,809 | -92.6% | 0.00% | -100.0% |
| Q1 2022 | $3,331,000 | +545.5% | 239,989 | +1207.2% | 0.00% | – |
| Q4 2021 | $516,000 | -73.7% | 18,359 | -68.2% | 0.00% | – |
| Q3 2021 | $1,962,000 | -74.7% | 57,744 | -69.5% | 0.00% | -100.0% |
| Q2 2021 | $7,742,000 | -22.1% | 189,493 | -23.2% | 0.00% | -40.0% |
| Q1 2021 | $9,933,000 | +52.2% | 246,712 | +123.5% | 0.01% | +66.7% |
| Q4 2020 | $6,526,000 | +6.9% | 110,368 | -12.1% | 0.00% | -25.0% |
| Q3 2020 | $6,106,000 | +36.5% | 125,557 | +35.8% | 0.00% | 0.0% |
| Q2 2020 | $4,472,000 | +1375.9% | 92,428 | +748.3% | 0.00% | – |
| Q1 2020 | $303,000 | – | 10,896 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Blue Water Life Science Advisors, LP | 3,030,434 | $23,152,516 | 15.55% |
| BERYLSON CAPITAL PARTNERS, LLC | 289,726 | $2,213,507 | 6.45% |
| Matrix Capital Management Company, LP | 11,572,590 | $88,414,588 | 1.69% |
| Pier Capital, LLC | 1,012,401 | $7,734,744 | 1.27% |
| VIKING GLOBAL INVESTORS LP | 29,993,708 | $229,151,929 | 1.15% |
| Eagle Health Investments LP | 607,860 | $4,644,050 | 1.07% |
| Triatomic Management LP | 130,805 | $999,350 | 0.84% |
| Aristotle Atlantic Partners, LLC | 1,880,567 | $14,367,532 | 0.80% |
| Senator Investment Group LP | 1,000,000 | $7,640,000 | 0.69% |
| ARK Investment Management | 9,201,245 | $70,297,512 | 0.61% |